Malek Cheikh, MD
Endocrinology, Diabetes & Metabolism · Baltimore, MDNPI 1235363128
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Novo Nordisk at 34.2% of the total. 2025 is the largest year on record at $4,792, more than ten times the $453 reported in 2019.
Across 73 payments — averaging $120.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Corcept Therapeutics$2K
- Lilly USA, LLC$2K
- AstraZeneca$774
- Medtronic$419
- Amgen$260
- plus $1K from 17 others
Across 1 payment — averaging $350.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$350
What the payments were for
- Consulting fees$4,91556%
- Speaking & faculty fees$1,40016%
- Food & beverage$2,33526%
- Education$1041%
- Gifts$591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 10 | $3,013 |
| Corcept Therapeutics | 10 | $1,725 |
| Lilly USA, LLC | 11 | $1,582 |
| AstraZeneca | 2 | $774 |
| Medtronic(2 entities) | 9 | $419 |
| Amgen | 5 | $260 |
| Radius Health, Inc. | 3 | $230 |
| Sanofi-aventis U.S. LLC | 4 | $200 |
| Bayer | 2 | $138 |
| BETA Bionics, Inc. | 1 | $88 |
| Mannkind Corporation | 1 | $59 |
| Abbott | 2 | $46 |
| Boehringer Ingelheim | 2 | $42 |
| Recordati_rare_diseases_inc. | 2 | $41 |
| Novartis | 1 | $31 |
| Lexicon Pharmaceuticals, Inc. | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Averitas Pharma Inc. | 1 | $23 |
| Cequr Corporation | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Gilead | 1 | $18 |
| AbbVie | 1 | $17 |
| Dexcom, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,813 in reported general payments places this provider in the 80th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 231 | $262,125 |
| TrulicityDulaglutide | 147 | $205,729 |
| TymlosAbaloparatide | 51 | $168,464 |
| MounjaroTirzepatide | 92 | $146,936 |
| JardianceEmpagliflozin | 127 | $145,420 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 37 | $73,613 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 45 | $38,025 |
| FarxigaDapagliflozin Propanediol | 26 | $35,684 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $26,248 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 84 | $25,839 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $20,642 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $16,307 |
| JanuviaSitagliptin Phosphate | 26 | $15,117 |
| Xigduo XrDapaglifloz Propaned/Metformin | 17 | $14,549 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $12,235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,582 | $354,809257 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $3,013 | $335,738268 claims |
| Radius Health, Inc.Tymlos | $230 | $168,46451 claims |
| Boehringer IngelheimJardiance, Tradjenta | $42 | $152,554140 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $200 | $38,02545 claims |
| AstraZenecaFarxiga | $774 | $35,68426 claims |
| AbbVieSynthroid | $17 | $1,30217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Baltimore
- Philip LevinBaltimore$489K
- Adrian DobsBaltimore$149K
- Todd BrownBaltimore$143K
- Roberto SalvatoriBaltimore$53K
- Nowreen HaqBaltimore$40K
- Asif MohamedBaltimore$31K
- Sherita GoldenBaltimore$27K
- Jean ParkBaltimore$13K
- Mansur ShomaliBaltimore$11K
- Paul SackBaltimore$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.